Bavarian Nordic A/S Announces Share Capital Increase
Bavarian Nordic A/S has recently made headlines for its noteworthy capital increase as a result of employee warrant exercises. The increase involved a nominal value of DKK 3,818,710, reflecting the company's strategic financial decisions.
Exercise of Employee Warrants
This capital increase took place without pre-emption rights for existing shareholders. The shareholders subscribed for new shares in cash, where a total of 363,156 shares were issued at a price of DKK 206.82 each and 18,715 shares at DKK 190.11 each. This remarkable effort resulted in total proceeds of DKK 78.7 million for Bavarian Nordic A/S.
Implications of the Capital Raise
The shares resulting from this increase will rank pari passu with the existing shares of Bavarian Nordic, ensuring that all shareholders have equal rights regarding the new and old shares. The company is preparing for these new shares to be publicly listed and traded on Nasdaq Copenhagen in the near future.
Current Share Capital Structure
Following the successful capital increase, the total nominal value of Bavarian Nordic A/S' share capital now stands at DKK 792,367,280. This total is composed of 79,236,728 shares, with each share having a nominal value of DKK 10. Thus, shareholders retain a voting scheme equivalent to their shareholding, translating to 79,236,728 votes.
Development of Company Articles
In conjunction with the capital increase, Bavarian Nordic plans to release revised Articles of Association on its company website shortly. This is a significant step in lobbying for transparency and governance in the company as it expects further growth and expansion.
About Bavarian Nordic
Bavarian Nordic is more than just a vaccine producer; it’s a global leader committed to improving public health through innovative vaccination solutions. The company specializes in producing mpox and smallpox vaccines and is a recognized supplier to governments, aiding public health preparedness against potential outbreaks.
Investor Relations Contact Information
For any inquiries or further information, Bavarian Nordic has set up dedicated lines for both European and U.S. investors. Rolf Sass Sørensen, Vice President of Investor Relations, can be reached for European matters via email at rss@bavarian-nordic.com or by telephone at +45 61 77 47 43. For U.S. investor inquiries, Graham Morrell from Gilmartin Group can be contacted at graham@gilmartinir.com or +1 781 686 9600.
Media Contact Information
Nicole Seroff is the Vice President of Corporate Communications. Media representatives can reach her at nise@bavarian-nordic.com or by calling +45 53 88 06 03.
Frequently Asked Questions
What prompted the capital increase by Bavarian Nordic A/S?
The capital increase was prompted by the exercise of employee warrants, which contributed to the firm’s financial stability.
How much capital was raised from the warrant exercises?
Bavarian Nordic A/S raised a total of DKK 78.7 million from the warrant exercises.
What does it mean for existing shareholders?
The new shares rank pari passu, meaning existing shareholders retain equal rights regarding their shares.
How many shares does Bavarian Nordic A/S have after the capital raise?
Following the capital increase, Bavarian Nordic A/S has a total of 79,236,728 shares outstanding.
Who can investors contact for more information?
Investors can contact Rolf Sass Sørensen for Europe and Graham Morrell for the U.S. for further inquiries about their investments.
